Drug Type Bispecific antibody |
Synonyms |
Target |
Action agonists, inhibitors, stimulants |
Mechanism TNFR agonists(Tumor necrosis factor receptor agonists), Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Discovery | Spain | - | |
Lung Cancer | Discovery | Spain | - | |
Ovarian Epithelial Carcinoma | Discovery | Spain | - | |
Pancreatic Cancer | Discovery | Spain | - | |
Testicular Neoplasms | Discovery | Spain | - | |
Thyroid Cancer | Discovery | Spain | - |